Zhejiang Cancer Hospital: Lymphoma trials

The registry lists 11 Lymphoma studies with Zhejiang Cancer Hospital as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular LymphomaNot yet recruitingNCT06918015Phase 2
• Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCLRecruitingNCT06832267Not applicable
• Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCLRecruitingNCT06832228Not applicable
• RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DELRecruitingNCT06674096Phase 2
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
• ZR2 Sequential Immunochemotherapy for Newly Treated MCLRecruitingNCT05992597Phase 2
• XPO-1 in Combination With RCHOP for DH/TH LymphomaRecruitingNCT05974085Phase 2
• ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
• A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area LymphomaStatus unknownNCT04860674Phase 2
• Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
• A Study of Bortezomib Combined With CHEP in Peripheral T Cell LymphomaStatus unknownNCT04061772Phase 2